BioCryst’s story hinges on one rare-disease drug that’s driving growth today, but also leaves the business exposed if rivals catch up or pricing pressure rises. See why the company’s push to broaden its pipeline may not arrive fast enough to protect that momentum.Read more
BioCryst’s rare-disease drug Orladeyo keeps adding new patients far later into its launch than many expected, raising the chance that the business grows faster and lasts longer than the market assumes. But with so much riding on one medicine, new rivals, tougher drug pricing rules, or a stumble in the next wave of treatments could quickly change the story.Read more
BioCryst’s growth story hinges on ORLADEYO, with new uses and a broader push into rare diseases that could widen its customer base over time. But that same reliance on one main medicine, plus growing competition and a narrowing focus after stepping back from Europe, could quickly change the outlook.Read more
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
